WO2010013836A1 - 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 - Google Patents
薬物内包アクティブターゲット型高分子ミセル、医薬組成物 Download PDFInfo
- Publication number
- WO2010013836A1 WO2010013836A1 PCT/JP2009/063838 JP2009063838W WO2010013836A1 WO 2010013836 A1 WO2010013836 A1 WO 2010013836A1 JP 2009063838 W JP2009063838 W JP 2009063838W WO 2010013836 A1 WO2010013836 A1 WO 2010013836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- drug
- target
- cell
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a drug using an active target type drug molecule having directivity for administration such as inflammation, neovascularization and intravascular administration.
- polyp p is arranged in a radiation with its position facing outwards and the object facing inward, and is connected in a state of maintaining a row of rows, the target is provided by endocytosis Is taken up by the part of the cell to be released, and when the column collapses, the object is released.
- the target position contained in the skeletal poly is a site having biological ability that can specifically bind to substances derived from living organisms and viruses to form a biological bond with the substance.
- molecules existing in living organisms, bacteria, fungi and viruses can be shown.
- a polymer may contain a target site by containing a protein, a pep and a compound that forms a bond with such a substance.
- the present invention provides a molecule as described above, which is pharmaceutically acceptable.
- Ming by incorporating the substance and position into the polymer cartridge, if the cell structure collapses before it is taken into the cell as a medication, the drug can be excreted out of the body by metabolism. It was decided. This makes it easier to avoid side effects compared to the conventional active target DDS.
- the simple explanation of the surface is a graph showing an example of the use of cancer cells by the molecules of light.
- Figure 2 is a graph showing the data related to the use of cancer cells by light molecules.
- 3 3 is a graph to show data on the time change of given by a given molecule.
- Fig. 4 is a graph showing the child's time-dependent change in the weight of an object due to the given molecule.
- 5 5 is a graph showing an example of the use of cancer cells by active target molecules.
- the bright molecular cell has a backbone polymer backbone polymer 2 as shown in a.
- the polymer has a compound having a target, a hydrophilic polymer segment 1 represented by a polyethylene glycol chain, and a poly segment 3 represented by amino.
- polyethylene glycol may be displayed in PEG.
- the polymer is a hydrophilic polymer segment 1 represented by a polyethylene glycol chain 1 And polymer segments represented by amino.
- the backbone poly r does not have a drug with a target
- the backbone poly does not have a target
- the polyskeleton skeleton poly is the target
- the molecule On may not contain polymer 3 consisting of a hydrophilic polymer segment polysegment having no target or drug, as shown in a.
- skeletal poly 2 of skeletal poly is arranged in a radial pattern as long as the target is outside and the drug is inside. Even if the dots are concentrated on the dots, they have a structure that has been made slightly.
- the molecule may be a polymer in which the polymer of the backbone polymer Q and the backbone polymer is in a dry state. When the molecule is bound in the state of radiation as shown in Fig. 5b, it is taken up by the site of cell endocytosis in the part of cell 5 that supplies n, and is displayed in the middle. It is thought that the material that has been produced by the decay of is released into the cell. More specifically, it is considered that when the skeletal polymer moves into the cell 5 and is sterically cleaved by an enzyme typified by sterase, the is released.
- the polymer column 8 breaks down before it is taken into the drug and is exposed to the drug. If it is fixed to the and exposed to the inside, it will be expelled from the body as soon as possible. .
- the polymer cell has a built-in safety mechanism that prevents the drug from damaging the normal cell if the cell structure collapses before it is taken up in a medicinal manner.
- the polymer is generally composed of a compound having a target position represented by 1 ZA and a block polymer.
- D a drug represented by D and a block polymer.
- Z is a compound having a position
- a and A are mutually independent polyethylene glycol segments and are mutually independent amino segments and D products.
- the polymer dot is attached to the end of the polyethylene glycol segment.
- It can be produced by condensing or adding a block polymer having a linkage such as a force aldehyde anomercaptoley and a compound having a target position.
- the polyethylene glycol segment of the polymer may have a name such as a hydryl group, but is in a CC with a carbon number of ⁇ if it has a branched alkyl or alkoxy, or has a hydroxyl group It is preferable.
- ano-segment examples include polyglutan or its stealth or ad conductor polyasparagine or its stealth or amide conductor.
- Such stealth or adduct can be prepared by reacting a corresponding xy compound or ananocompound having a reactive conductor of polyglutamine or riaspartic acid, such as stealth.
- CC with ⁇ 6 carbon atoms.
- alkylphenols in cholesterol or cholesterol having a branch number which can be exemplified by alkyls in CC.
- Polymers in polymer polymers are block polymers are For example, YPG CH CH CH NH Y, which is the method described in Report 2 3 3, may be protected or represents a substitution and starts with dehydrating N-carboxy-benzyl- "glutamate or N-carbo B-benzyl-" aspartate. It can be achieved by adding as much reaction as possible. C to introduce higher than benzyl. Substitute the alkyl group with a C-C alkyl group. A compound having a hydroxyl group or an amino group for dehydration may be introduced into polyglutamine using a mixture such as cyclo and propyl carbo.
- the polyt has a structure represented by the following a or general b
- the skeleton poly has a structure represented by the following a or general.
- R is a compound having a position
- R may have a hydroxyl group at the end, and an alkyl group in the range of a prime number to “” is CH p ”is a number in the range of to from“ CH p C ”.
- R is a hydrogen atom or
- Or is a number independently of each other in the range of ⁇ 45, r is independently of each other a number in the range of 2 to 8, and has a total of ⁇ 7 linkages It may be a drug atom or an existing atom.
- rT are preferably numbers in the range of 2 to, and more preferably numbers in the range of 2 to.
- skeletal polyt and skeletal polyt 2 exist in the range of ⁇ .
- examples of the compound having a protein include a protein, a pep or a compound that forms a bond with a substance derived from a living body or a virus. These proteins are bound to substances derived from viruses and viruses Examples include speri and epithelial EGF.
- examples of the body include receptors that are expressed on the surface represented by cancer cells, and bodies that recognize er2, 20 F, and 2 that are the origin of the cell surface. It may be a Narnal body or a Licronal body. As long as the body has a length capable of specifically recognizing an antigen (Fab 2 Fab can be exemplified.
- insulin L “and a conductor thereof can be exemplified.
- Glucose, mannose galactose and fucose can be exemplified as follows:
- a compound having a substance that forms a bond is a substance derived from a virus
- the cell is destroyed by the infected virus when supplying the substance. Therefore, in this specification, when the target is a virus-derived substance, the target 4 is supplied to the cells existing in the vicinity of the target. If a substance derived from a virus is present in the cell, there is a high possibility that the virus will be infected. There is a significance to supply the drug to.
- Examples include Lislo Ishin, Clarislo Isin, Isin Chloramfecole, Banco Ishin, Fulcosol Pitalabine Asilovir Sin Jin Sal Davin Jin, Bill Océville Bill, Ritonavi.
- Examples of conductors include bin rabin (ra ne crophora bin (rab ne, bin ea ne, streptozocin rep ozo) doxidine o ur d ne fludarabine.
- the salt is not a salt, and examples of the derivatives of rons include au ne abe ne 30 862. 7
- the skeletal polymer can have a structure in which the acid group is stereo-bonded to the polyglutan group.
- a structure in which one object is combined with a number of groups in polyglutane and a structure in which the above block polymer part is bridged through one object are also included in polyt p. I will do it.
- a bright molecule can be produced, for example, by mixing a polymer and a skeletal polymer in an aqueous liquid and allowing them to self-like in a cellular form.
- the light molecule can be obtained by mixing a skeletal polymer and a skeletal polymer in an aqueous liquid and self-weaving them into a cellular form, and then adding a compound having a target site to the skeleton It can also be made by bonding to the end of the aqueous segment.
- the active target DS represented by the molecular conjugate described in 1 is formed by binding a compound having a target site to a block polymer in which a drug is sterilized.
- the compound having the target position in the block polymer may be bound or substituted, and the compound may be lost.
- the drug may break down in the process of binding the compound.
- Actuate Target S it has been difficult to prepare Actuate Target S conventionally.
- an apparent molecule can easily form an acta- tate molecule while avoiding the agent.
- pharmaceutically acceptable Can can also be provided.
- dilutions that are used in the field of surgery and which are mouthpieces, purifications suitable for the production of cryogens, deionization and are preferred.
- the clear route is preferably subcutaneous, venous arterial oral administration, and venous injection is particularly preferred. Usage of drugs Although it is adjusted according to the patient's age and gender and the patient's state of health, it is calculated as a drug calculation. Will be explained in more detail.
- the compound having the 2nd position has transferrin, and the drug is camptocin (a macromolecule containing CPT, transferrin campto
- a campto syndicate u was constructed as follows. After c was dissolved in 8 formaldehyde, 37 camptocin was added. In addition, it is PGD in this c, it is the average of aspartic acid, and is the side sulfonic acid of aspartic acid. And 8 NV SopropylCarbo (Industry Chemistry and 3 Methyl Anodi.
- transfer f may be displayed O to H
- Tf was solved by adding terylenediamine D purification. Add 3 trf pierced earrings so that the degree of HO becomes and the degree of DTA becomes, followed by 3. The reaction sequence 0 and sodium O-phosphate (H7 D polymer) obtained in this manner were recovered.
- This 75 was mixed with the above cell 7 and made 2 into C to react with the ray Tf of a e de L to form a bone polymer containing transferrin polymer.
- This transferrin polymer has the structure represented by a above. PG Da. Of sodium phosphate in this
- the Tf was removed by adding ephar se L 4 x 2O sodium H5 adjusted to 5 by adding ammonium.
- the polythel was used as a xelose pu.
- transferrin was formed as a high molecular compound containing transferel as a target compound and encapsulating xel as a drug. did.
- the deviation of PG constituting the block polymer part of the skeleton polymer and the polymer was also made O Da.
- p is in a state e p in which xel is bonded to p u via an ester bond and has a structure represented by a above.
- the polyt was created as follows. 7 KD F of 5 O polytinglycopolyglutamine block polymer pc with one end of polyglutanoic acid
- the noxel no har an L d was added.
- it is the average molecule of PG in c, it is the average of glutamic acid, and the side boronic acid of ruthenic acid.
- the polymer was then reduced in pressure, and the poly was reduced in pressure by adding the poly from the collection in powder form to O with Xanthi. -By letting the room temperature
- G-Xel which is a polymer encapsulating DTX
- a DTX compound (pu was formed in the same manner as in the implementation).
- a PG Da and a polymer having a ray group at the G end (aed L was prepared.
- the pu of 5 poly and the pu were processed in the same way after purification and addition to the sample trial.
- the cell (recovered.
- the cell contains p and a ei L arranged in a radial pattern. In the vial where the recombinant human G yscms was e.
- This EG F poly has a structure represented by a. Reaction obtained
- the corresponding EG was removed by epharose L 4 ⁇ 3 sodium H7.
- the collected cell was subjected to ultracontamination to obtain a liquid containing EG xel.
- a RANK ”body and a mouse (a polymer encapsulating V, RANK” body bound lolimus was prepared as follows.
- a lolimus conjugate p as a skeletal polyp was formed as follows. Polyethylene glycol block polymer in which one end of polyglutamic acid is chilled was dissolved in O DF), and 2 more lolimus L ⁇ ⁇ was added. In addition, the average numerator of PG on this pc
- the polymer was reduced to pressure with a xane (), and then the polymer was depressurized. After adding the polymer to OO, the pressure was reduced.
- the polymer obtained was dissolved at 25 ° C. by dissolving it in room temperature at room temperature. When the amount of lolimus was measured, it was 2 children per poly, and this p is in the state ep where belolimus is bound to pu via a steal bond, which is the structure represented by a above PG OkD a.
- RANK as a polymer ”body binding poly did.
- a polymer ed with a ray group at the PG end was prepared.
- Ae de L was added to the sample vial with sodium phosphate H7. .
- sonication was performed using a pio-slaptor machine maker, and a liquid containing de P was collected using Filter Milli III p.
- the collected cell was subjected to ultra-contra molecule to obtain a liquid containing a RANK binding polymer.
- Transferrin lolimus which is a macromolecule containing V as a drug and having a transly as a compound having a position, was prepared as follows.
- the transferrin poly as a polyt was prepared as follows. First, a liquid containing de was obtained in the same manner as in the implementation.
- the transferrin solution was prepared by dissolving the transtransferring gamma Aldrich. To this transferrin u, add DTA purification of 2 H 2 O to add 34 trout pierced earrings to a HO degree of 5 and a DTA degree of 2, then 3.
- transferrin poly has a structure represented by a. Reaction epharose L4 x OM Phosphorus Sodium (H7 was used to remove the corresponding SH transfer. After the collected cells were cut off by ultrafiltration, 3 a 3 H was added to adjust H to 7, and O-stain solution was added at room temperature.
- the Tf DTX was prepared as follows. PG DTX prepared in step 2 was suspended in an O sample vial by adding 2 OM sodium phosphate H7. . After day and night at C, use pio israptor machine rn to sonicate and filter J
- Tf CPT In order to facilitate polymer cell encapsulating campto without any compound having a position, Tf CPT is called as follows. It was purified and added to the uO sania prepared in step 2 and suspended. . After day and night in C, biodisrupter
- Tf mpty A compound having Tf as a compound having "" "" positions.
- Tf mpty was called as follows.
- Poly a e d L having a ray group at the P G end was prepared. PEG O Da to polymer. A e de was added to a sample vial of sodium phosphate H7. . After day and night at C, the liquid containing L was collected by using a bio-disrupter machine o ern and water-cooled sonication with a filter millie.
- Tf was solved by adding the H and OO M tylenediamine DTA purification to human TfO. Then, add 3 trout pierced earrings so that the Ho is 5 and the DTA is. C. Reactions obtained in this way 20 DTA polymer was recovered.
- Tf DTX cells Comparison of Tf DTX cells with 2 Tf DTX cells.
- the human MDA 3 cells entered from EuropeanCoIIeCtonOfCeCure via the DS DS biomedical formula company were evaluated as follows based on S.
- s40 for the wavelength 5 line was measured, and Ce gro h was calculated based on the following formula.
- s450 of control means the degree from the time when the above-mentioned nutrition was carried out using a nutrient solution not containing DTX.
- test 2 the sample solution was added and changed to 72, then eagen was added per well.
- the cells were prepared with Tf DTX for comparison with Tf DTX.
- FIG. 2 is a graph showing the DA 2 cell versus the xelose degree. This is the same as in the graph with the horizontal axis and angle in the graph.
- the rubber in Senichi is SD.
- Tf DTX against 23 cells was exerted at a significantly lower DTX degree than T f DTX.
- the test was carried out using a human fistula adenocarcinoma entered from ccnr m2on as a cell through Sumisho Far International Ltd. In the same way, the cells were prepared by changing the interval between 8 to 8.
- Test 5 23 human vesicles were used, and cells were prepared in the same manner as the cells.
- the chemistry was heated at C for a while.
- the obtained reaction was collected and neutralized by adding N OH.
- the CPT degree was measured by displacing the solution with 2 ammonium H3, filling this sample solution into an HP C sample vial, and analyzing the HP under the following conditions.
- Fig. 5 is a graph showing 31 cells for Tf degrees. The amount of in the sample of the graph is calculated as Tf degrees. This is when Tf empty is added, when Tf DTX is added, and when T solution is added. The rubber in the data is. Tf as shown in graph 5
- Xelels showed superior cells to DA vesicles, but Tf and Tf empty had no cells.
- 84 Using 23 human vesicles made of 0 and S, 7 C 5 C was fed until needed to grow. The cells were inoculated subcutaneously into female nude nu nu 5, manufactured by Jars Lipa Co., Ltd. 3 6 cells inoculated
- the schedule was 3 tails every other time, and the following 3 groups and the weight of the mouse were set to 3.
- the number of per mouse is eight.
- Tf DTX cells (O per k of the DTX per unit of O 3 is a graph showing the time change of.
- the graph shows the relative to the beginning of the test, and the horizontal axis shows the ays from the start of the test.
- the arrow in the middle shows the timing of drug administration, the child of the control group, the child of the fDTX cell group, and the data of the Tf DTX cell group. This shows the relative to the weight of the mouse at the start of the test in the same way as in the graph of the horizontal axis in the graph of, the black arrow, and the angle in the graph.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09803068.7A EP2281576B1 (en) | 2008-07-29 | 2009-07-29 | Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
US12/672,496 US8741339B2 (en) | 2008-07-29 | 2009-07-29 | Active targeting polymer micelle encapsulating drug, and pharmaceutical composition |
CA2695611A CA2695611C (en) | 2008-07-29 | 2009-07-29 | Active targeting polymer micelle encapsulating drug, and pharmaceutical composition |
PL09803068T PL2281576T3 (pl) | 2008-07-29 | 2009-07-29 | Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna |
JP2009551910A JP4538666B2 (ja) | 2008-07-29 | 2009-07-29 | 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 |
KR1020117014312A KR101468268B1 (ko) | 2008-07-29 | 2009-07-29 | 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물 |
DK09803068.7T DK2281576T3 (da) | 2008-07-29 | 2009-07-29 | Aktiv målsøgende polymermicelle med deri indkapslet medikament samt medicinsk sammensætning |
AU2009277456A AU2009277456B2 (en) | 2008-07-29 | 2009-07-29 | Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
CN2009801004628A CN101808668B (zh) | 2008-07-29 | 2009-07-29 | 药物内包活性靶向型高分子微团、医药组合物 |
ES09803068T ES2432152T3 (es) | 2008-07-29 | 2009-07-29 | Micela polimérica de tipo de direccionamiento activo que porta fármaco encerrado en ella y composición medicinal |
HK11102396.3A HK1148216A1 (en) | 2008-07-29 | 2011-03-10 | Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-194825 | 2008-07-29 | ||
JP2008194825 | 2008-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010013836A1 true WO2010013836A1 (ja) | 2010-02-04 |
Family
ID=41610525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/063838 WO2010013836A1 (ja) | 2008-07-29 | 2009-07-29 | 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8741339B2 (ja) |
EP (1) | EP2281576B1 (ja) |
JP (1) | JP4538666B2 (ja) |
KR (2) | KR101468268B1 (ja) |
CN (1) | CN101808668B (ja) |
AU (1) | AU2009277456B2 (ja) |
CA (1) | CA2695611C (ja) |
DK (1) | DK2281576T3 (ja) |
ES (1) | ES2432152T3 (ja) |
HK (1) | HK1148216A1 (ja) |
PL (1) | PL2281576T3 (ja) |
PT (1) | PT2281576E (ja) |
WO (1) | WO2010013836A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012133884A1 (ja) * | 2011-03-31 | 2012-10-04 | ナノキャリア株式会社 | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 |
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524784B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
WO2014185504A1 (ja) | 2013-05-17 | 2014-11-20 | ナノキャリア株式会社 | ポリマーミセル医薬組成物 |
WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
WO2017218825A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
WO2018025699A1 (ja) * | 2016-08-02 | 2018-02-08 | 日本化薬株式会社 | アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途 |
US10961301B2 (en) | 2011-04-01 | 2021-03-30 | Yale University | Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair |
JP2023510896A (ja) * | 2020-01-15 | 2023-03-15 | スーパーノヴァ バイオ カンパニー リミテッド | 局所脂肪減少用気体発泡型ミセル |
WO2023056450A1 (en) | 2021-09-30 | 2023-04-06 | Yale University | Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity |
WO2023176809A1 (ja) * | 2022-03-17 | 2023-09-21 | 日油株式会社 | ポリエチレングリコール誘導体の製造方法 |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013073697A1 (ja) | 2011-11-17 | 2013-05-23 | 国立大学法人 東京大学 | フェニルボロン酸基が導入されたブロックコポリマーおよびその使用 |
US9808480B2 (en) | 2012-04-27 | 2017-11-07 | Nanocarrier Co., Ltd. | Unit structure-type pharmaceutical composition for nucleic acid delivery |
US10993960B1 (en) | 2014-05-08 | 2021-05-04 | Kawasaki Institute Of Industrial Promotion | Pharmaceutical composition |
US20180092859A1 (en) * | 2015-04-02 | 2018-04-05 | The Research Foundation For The State University Of New York | A Supramolecular Chitosan Complex Drug Delivery Platform |
WO2019044937A1 (ja) | 2017-08-31 | 2019-03-07 | 国立大学法人 東京大学 | 核酸搭載ユニット型ポリイオンコンプレックス |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087497A2 (en) | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
WO2007048121A2 (en) * | 2005-10-20 | 2007-04-26 | Centocor, Inc. | Methods of preparing targeted immunoliposomes |
JP2007119436A (ja) * | 2005-10-31 | 2007-05-17 | Miyazaki Prefecture | 肝疾患治療用又は予防用の血中滞留型多相エマルション製剤及びその製造方法 |
WO2007066781A1 (ja) * | 2005-12-05 | 2007-06-14 | Nanocarrier Co., Ltd. | フッ素系有機溶媒を用いた薬物封入ポリマーミセルを含有する医薬組成物の製造方法 |
WO2008047948A1 (fr) * | 2006-10-19 | 2008-04-24 | Nanocarrier Co., Ltd. | Copolymère bloc pour complexe médicamenteux et composition pharmaceutique |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020197261A1 (en) * | 2001-04-26 | 2002-12-26 | Chun Li | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
US7371781B2 (en) * | 2003-09-22 | 2008-05-13 | University Of Utah Research Foundation | Tumor environment-induced ligand-expressing nanocarrier system |
US8697031B2 (en) * | 2004-06-04 | 2014-04-15 | Case Western Reserve University | Dual function polymer micelles |
AU2006231452B2 (en) * | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
JP4992090B2 (ja) * | 2005-05-02 | 2012-08-08 | 国立大学法人 東京大学 | 静電結合型高分子ベシクル |
EP2011516A4 (en) * | 2006-04-24 | 2010-06-23 | Nanocarrier Co Ltd | PROCESS FOR THE PRODUCTION OF A POLYMERIC MICELLE THAT CONTAINS A CHEMICAL PRODUCT OF LOW MOLECULAR WEIGHT ENCAPSULATED IN IT |
EP2131814A4 (en) * | 2007-02-26 | 2011-08-03 | Wisconsin Alumni Res Found | POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS |
-
2009
- 2009-07-29 EP EP09803068.7A patent/EP2281576B1/en not_active Not-in-force
- 2009-07-29 PT PT98030687T patent/PT2281576E/pt unknown
- 2009-07-29 DK DK09803068.7T patent/DK2281576T3/da active
- 2009-07-29 PL PL09803068T patent/PL2281576T3/pl unknown
- 2009-07-29 AU AU2009277456A patent/AU2009277456B2/en not_active Ceased
- 2009-07-29 CA CA2695611A patent/CA2695611C/en not_active Expired - Fee Related
- 2009-07-29 KR KR1020117014312A patent/KR101468268B1/ko active IP Right Grant
- 2009-07-29 CN CN2009801004628A patent/CN101808668B/zh not_active Expired - Fee Related
- 2009-07-29 WO PCT/JP2009/063838 patent/WO2010013836A1/ja active Application Filing
- 2009-07-29 US US12/672,496 patent/US8741339B2/en active Active
- 2009-07-29 JP JP2009551910A patent/JP4538666B2/ja not_active Expired - Fee Related
- 2009-07-29 ES ES09803068T patent/ES2432152T3/es active Active
- 2009-07-29 KR KR1020107006136A patent/KR20100055498A/ko active Application Filing
-
2011
- 2011-03-10 HK HK11102396.3A patent/HK1148216A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087497A2 (en) | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
WO2007048121A2 (en) * | 2005-10-20 | 2007-04-26 | Centocor, Inc. | Methods of preparing targeted immunoliposomes |
JP2007119436A (ja) * | 2005-10-31 | 2007-05-17 | Miyazaki Prefecture | 肝疾患治療用又は予防用の血中滞留型多相エマルション製剤及びその製造方法 |
WO2007066781A1 (ja) * | 2005-12-05 | 2007-06-14 | Nanocarrier Co., Ltd. | フッ素系有機溶媒を用いた薬物封入ポリマーミセルを含有する医薬組成物の製造方法 |
WO2008047948A1 (fr) * | 2006-10-19 | 2008-04-24 | Nanocarrier Co., Ltd. | Copolymère bloc pour complexe médicamenteux et composition pharmaceutique |
Non-Patent Citations (3)
Title |
---|
ASAHINA H; YAMAZAKI K; KINOSHITA I ET AL., BRITISH JOURNAL OF CANCER, vol. 95, 2006, pages 998 - 1004 |
BAE Y ET AL., BIOCONJ UGATE CHEM., vol. 18, 2007, pages 1131 - 1139 |
See also references of EP2281576A4 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524784B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8629186B2 (en) | 2009-04-30 | 2014-01-14 | Intezyne Technologies, Inc. | Polymer micelles containing anthracyclines for the treatment of cancer |
US9561284B2 (en) | 2011-03-31 | 2017-02-07 | Nanocarrier Co., Ltd. | Pharmaceutical composition containing a block copolymer bound to a boronic acid compound |
JP5086497B1 (ja) * | 2011-03-31 | 2012-11-28 | ナノキャリア株式会社 | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 |
KR20140038376A (ko) * | 2011-03-31 | 2014-03-28 | 나노캬리아 가부시키가이샤 | 보론산 화합물을 함유한 블록 공중합체를 포함하는 의약 조성물 |
KR101869125B1 (ko) * | 2011-03-31 | 2018-06-19 | 나노캬리아 가부시키가이샤 | 보론산 화합물을 함유한 블록 공중합체를 포함하는 의약 조성물 |
WO2012133884A1 (ja) * | 2011-03-31 | 2012-10-04 | ナノキャリア株式会社 | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 |
RU2569847C2 (ru) * | 2011-03-31 | 2015-11-27 | Нанокэрриер Ко., Лтд. | Фармацевтическая композиция, содержащая блок-сополимер, включающий соединение бороновой кислоты |
US10961301B2 (en) | 2011-04-01 | 2021-03-30 | Yale University | Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair |
WO2014185504A1 (ja) | 2013-05-17 | 2014-11-20 | ナノキャリア株式会社 | ポリマーミセル医薬組成物 |
KR20160007529A (ko) | 2013-05-17 | 2016-01-20 | 나노캬리아 가부시키가이샤 | 중합체 미셀 의약 조성물 |
JP5692887B1 (ja) * | 2013-05-17 | 2015-04-01 | ナノキャリア株式会社 | ポリマーミセル医薬組成物 |
WO2017218825A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
US11590242B2 (en) | 2016-06-15 | 2023-02-28 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
WO2018025699A1 (ja) * | 2016-08-02 | 2018-02-08 | 日本化薬株式会社 | アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途 |
JPWO2018025699A1 (ja) * | 2016-08-02 | 2019-05-30 | 日本化薬株式会社 | アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途 |
US10973762B2 (en) | 2016-08-02 | 2021-04-13 | Nippon Kayaku Kabushiki Kaisha | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition |
JP2023510896A (ja) * | 2020-01-15 | 2023-03-15 | スーパーノヴァ バイオ カンパニー リミテッド | 局所脂肪減少用気体発泡型ミセル |
JP7485405B2 (ja) | 2020-01-15 | 2024-05-16 | スーパーノヴァ バイオ カンパニー リミテッド | 局所脂肪減少用気体発泡型ミセル |
WO2023056450A1 (en) | 2021-09-30 | 2023-04-06 | Yale University | Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity |
WO2023176809A1 (ja) * | 2022-03-17 | 2023-09-21 | 日油株式会社 | ポリエチレングリコール誘導体の製造方法 |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Also Published As
Publication number | Publication date |
---|---|
KR20100055498A (ko) | 2010-05-26 |
PL2281576T3 (pl) | 2013-12-31 |
US8741339B2 (en) | 2014-06-03 |
AU2009277456B2 (en) | 2011-05-26 |
CN101808668A (zh) | 2010-08-18 |
CA2695611C (en) | 2011-02-01 |
EP2281576A1 (en) | 2011-02-09 |
JP4538666B2 (ja) | 2010-09-08 |
CA2695611A1 (en) | 2010-01-29 |
AU2009277456A1 (en) | 2010-02-04 |
JPWO2010013836A1 (ja) | 2012-01-12 |
HK1148216A1 (en) | 2011-09-02 |
DK2281576T3 (da) | 2013-10-28 |
KR20110075054A (ko) | 2011-07-05 |
CN101808668B (zh) | 2012-06-27 |
KR101468268B1 (ko) | 2014-12-02 |
ES2432152T3 (es) | 2013-12-02 |
US20100221320A1 (en) | 2010-09-02 |
EP2281576B1 (en) | 2013-07-24 |
PT2281576E (pt) | 2013-10-01 |
EP2281576A4 (en) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010013836A1 (ja) | 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 | |
CN100549044C (zh) | 可生物降解的交联聚乙烯亚胺及其应用 | |
CA2145502A1 (en) | Alginate-bioactive agent conjugates | |
RU2727156C2 (ru) | Система доставки на основе бортезомиба | |
EP2997979A1 (en) | Polymeric micelle pharmaceutical composition | |
CN101374531A (zh) | 采用透明质酸作为不同类别治疗活性剂的载体分子 | |
JP2019519508A (ja) | マルチアーム重合標的抗がんコンジュゲート | |
KR102279429B1 (ko) | 멀티 암 표적 항암 콘쥬게이트 | |
KR101117861B1 (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
WO2022052413A1 (zh) | 具有不对称膜结构的载药聚合物囊泡及其制备方法与在制备治疗急性髓系白血病药物中的应用 | |
CN107266384B (zh) | 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法 | |
CN109464397A (zh) | 一种基于生物矿化的氧化石墨烯多药共载系统及其制备方法和应用 | |
CN108888774B (zh) | 一种雷公藤红素-树状大分子缀合物及其制备方法与应用 | |
CN103976976A (zh) | 一种包载重组人生长激素缓释药物微囊的制法 | |
CN108997575B (zh) | 聚乙二醇-b-聚酪氨酸-硫辛酸共聚物、聚多肽胶束及其制备方法与应用 | |
CN102652836A (zh) | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 | |
CN102617852B (zh) | 马来酰亚胺-聚谷氨酸-天冬氨酸聚合物和其复合物、及其制备方法和用途 | |
CN105037739A (zh) | 具有精氨酸穿膜作用的还原敏感型聚合物及其制备方法与应用 | |
CN110801519B (zh) | 高肿瘤富集渗透的纳米药物载体及其制备方法和应用 | |
CN114796522A (zh) | 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物 | |
CN111110857A (zh) | 一种长效缓释的聚乙二醇修饰抗肿瘤药物及其制备方法 | |
CN114276390B (zh) | 一种用于抗肿瘤药物递送的二硫代氨基甲酸酯衍生物纳米药物及其制备方法与应用 | |
CN108354896B (zh) | 一种雷替曲塞水凝胶及其制备方法和用途 | |
Guo | Cationic Amino Acid-Modified Camptothecin Prodrugs with Typical Helix Self-Assembly for Combination Cancer Therapy | |
US20130259944A1 (en) | Methods and compositions for treating cancer with platinum particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980100462.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2009551910 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2695611 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009803068 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107006136 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009277456 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09803068 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009277456 Country of ref document: AU Date of ref document: 20090729 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12672496 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 536/CHENP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |